Cutaneous squamous cell carcinoma metastatic to parotid - analysis of prognostic factors and treatment outcome

World Journal of Surgical Oncology

Gerald B Fogarty²  Ron Bova¹  Robin Yeong Hong Goh³ 

[1] Department of Head and Neck Surgery, St Vincent’s Hospital, 390 Victoria Street, Darlinghurst, NSW, 2010, Australia;Radiation Oncology, Mater Hospital, 25 Rocklands Rd, Crows Nest, NSW, 2065, Australia;Faculty of Medicine, University of New South Wales, Botany Street, Sydney, NSW, 2052, Australia

关键词: Skin cancer;    Radiotherapy;    Parotidectomy;    Neck lymph nodes;    Metastasis;    Immune suppression;    Head and neck;    Audit;   

Others  :  827652
DOI  :  10.1186/1477-7819-10-117

 received in 2012-01-22, accepted in 2012-06-25,  发布年份 2012

【 摘 要 】

Background

Cutaneous squamous cell carcinoma (cSCC) comprises 20% of all skin cancer of the head and neck. A minority will metastasize to regional parotid lymph nodes. This study evaluates the St Vincent’s Hospital, Sydney experience between 1996 and 2006.

Methods

A retrospective review was performed of patients who were evaluated in our multidisciplinary head and neck clinic with metastatic cSCC to parotid, and all treatment and pathologic details were reviewed. Statistical analysis, including univariate and multivariate analyses, were performed using Cox proportional hazards regression mode, overall and disease-specific survival were estimated by the Kaplan-Meier method.

Results

Sixty-seven patients were identified. Some 90 % were male, and with a mean age of 72.8 years. One died on the first postoperative day. The remaining 66 patients received radiotherapy. For these 66 patients, the two-year and five-year overall survival rate was 0.83 and 0.72, respectively. The two-year and five-year disease-free survival rate was 0.91 and 0.83 respectively. Overall survival was only significantly correlated to the extent of parotidectomy (superficial versus total; P = 0.0256). Margin status was available in 59 patients. The only parameter that significantly correlated with disease-free survival was margin status (close/negative versus positive P = 0.0348). Other parameters of immune suppression, perineural invasion, extra capsular extension, degree of tumour differentiation, number of positive nodes, extent of neck dissection and radiotherapy dosage delivered did not confer prognostic significance.

Conclusions

This study confirmed the association of adverse prognostic implication of positive margins on disease-free survival. Immune compromise was not a significant factor in this small group. Further studies are warranted in this population.

【 授权许可】

   
2012 Goh et al.; licensee BioMed Central Ltd

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, Coldiron BM: Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010, 146:283-287.
• [2]Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG: Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006, 184:6-10.
• [3]Australian cancer incidence and mortality workbooks (ACIM). Canberra: AIHW; 2010. Retrieved from [www.aihw.gov.au/cancer/data/acim_books/index.cfm webcite] on 13 October 2011
• [4]Kwa RE, Campana K, Moy RL: Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992, 26:1-26.
• [5]O’Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS, Jackson MA: Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck 2002, 24:417-422.
• [6]Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, Som PM, Day TA, Committee for Neck Dissection Classification, American Head and Neck Society: Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg. 2008, 134:536-538.
• [7]Ch’ng S, Maitra A, Lea R, Brasch H, Tan ST: Parotid metastasis - An independent prognostic factor for head and neck cutaneous squamous cell carcinoma. Journal of Plastic, Reconstructive & Aesthetic Surgery 2006, 59:1288-129.
• [8]Chua MS, Veness MJ, Morgan G, Shakespeare T, Hehir A, Gebski V, Cakir B, Tiver KW: Parotid lymph-node metastases from cutaneous squamous-cell carcinomas: treatment outcome and prognostic factors following surgery and adjuvant radiotherapy. Australas Radiol 2002, 46:174-179.
• [9]Palme CE, O’Brien CJ, Veness MJ, McNeil EB, Bron LP, Morgan GJ: Extent of parotid disease influences outcome in patients with metastatic cutaneous squamous cell carcinoma. Archives of otolaryngology- head & neck surgery 2003, 129:750-753.
• [10]Dona E, Veness MJ, Cakir B, Morgan GJ: Metastatic cutaneous squamous cell carcinoma to the parotid: the role of surgery and adjuvant radiotherapy to achieve best outcome. ANZ J Surg 2003, 73:692-696.
• [11]Veness MJ, Palme CE, Smith M, Cakir B, Morgan GJ, Kalnins I: Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (nonparotid): a better outcome with surgery and adjuvant radiotherapy. Laryngoscope 2003, 113:1827-1833.
• [12]Veness MJ, Morgan GJ, Palme CE, Gebski V: Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 2005, 115:870-875.
• [13]Martinez JC, Otley CC, Stasko T, Euvrard S, Brown C, Schanbacher CF, Weaver AL: Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003, 139:301-306.
• [14]Veness MJ, Quinn DI, Ong CS, Keogh AM, Macdonald PS, Cooper SG, Morgan GW: Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 1999, 85:1758-1764.
• [15]O’Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS: Incidence of cervical node involvement in metastatic cutaneous malignancy involving the parotid gland. Head Neck 2001, 73:744-748.
• [16]Bova R, Saylor A, Coman WB: Parotidectomy: review of treatment and outcomes. ANZ J Surg 2004, 74:563-568.